Ann: European RAT Clinical Trial Halted to Refocus Initiatives, page-73

I agree that strong management is everything and it is a decisive call, but ultimately the call was made because of yet another failure to pass even regulatory hurdles, let alone commercialise. It is a relentless pattern with this company - couldn’t get a test up in a pandemic - and no matter what word you use to describe it, “outlier” or otherwise, yet again the tech has not cut the mustard.
ADO will remain R&D for many more months, reliant upon a tech the entire bloody world has had a chance to view but nobody wants, and a capital raise is coming to ensure survival.
Strong management will be better for a long-term view but I think the share price will nose dive short-medium term. I also think Surges is desperate to get out of his position, which is why he’s calling it a buy right now to minimise the damage.
Hey, I could be wrong and the price steadies. We’ll see.